These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000630-37 A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability and efficacy of the CCR1 antagonist ZK 811752, given orally in a dose of 600 mg t... 2007-02-15 due-trials
Reported results 2004-000811-24 Multicenter, double-blind, randomized, pleacebo-controlled study to evaluate the oral low-dose estradiol preparations SH T 04170 E (100 µg estradiol) and SH T 04170 F (190 µg estradiol) in postmenopau... 2005-01-06 due-trials
Reported results 2004-000821-31 Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethinyles... 2006-04-20 due-trials
Reported results 2004-001545-15 Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo de Testogel® (testosterona 50–100mg) para evaluar su eficacia y seguridad en hombres que presentan síntomas típicos de deficit ... 2007-10-10 due-trials
Reported results 2004-001613-34 A multi-center, double-blind, double-dummy, controlled, randomized study to evaluate cycle control and safety of a four-phasic oral contraceptive containing estradiol valerate and dienogest (SH T00658... 2006-09-05 due-trials
Reported results 2004-001614-13 A single-center, open-label, controlled, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) as compared to a sequen... 2006-03-24 due-trials
Reported results 2004-002099-40 Double-blind, randomized, reference-controlled, multicenter, parallel-group study to compare the efficacy and safety of Advantan ointment once daily with Protopic 0.03% ointment twice daily over max. ... 2006-08-23 due-trials
Reported results 2004-002290-22 Phase II open-label study to investigate the efficacy and safety of PTK787/ZK222584 orally administered once daily or twice daily at a total daily dose of 1250 mg as second-line monotherapy in patient... 2008-07-17 due-trials
Reported results 2004-002291-42 Multi-center, open, randomized, dose finding phase II study to investigate for a maximum of three years ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing in vitro 12 µg/... 2008-12-09 due-trials
Reported results 2004-002395-41 Phase II study of MS-275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma 2006-07-27 due-trials
Reported results 2004-002673-22 Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabas cream during a maintenance phase of 16 we... 2006-06-13 due-trials
Reported results 2005-000597-53 Phase II study to investigate the efficacy and safety of ZK 219477 as first-line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC) 2007-04-17 due-trials
Reported results 2005-000635-15 Randomized, multicentre, prospective, two-arm, open-label Phase II study to investigate the efficacy and safety of two ZK219477 i.v. infusions (3-hour infusion of 16mg/m2 versus 0.5-hour infusion of 1... 2007-06-26 due-trials
Reported results 2005-001540-23 A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. 2006-12-05 due-trials
Reported results 2005-001727-11 A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud... 2008-12-05 due-trials
Reported results 2005-002547-66 Intra-individual open-label multicenter comparison study of magnetic resonance angiography (MRA) with the blood pool contrast agent Vasovist® and a conventional extracellular contrast agent with intra... 2007-02-17 due-trials
Reported results 2005-003216-30 Ensayo clínico de fase II prospectivo, multicéntrico, aleatorizado de grupos paralelos, abierto, para estudiar la eficacia, seguridad y tolerabilidad de 2 dosis de ZK 219477 (16 y 12 mg/m2 de área de ... 2009-01-15 due-trials
Reported results 2005-004340-32 A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional ... 2008-05-27 due-trials
Completed, but no date 2005-005211-21 A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years bad-data
Reported results 2005-005581-36 Estudio fase II aleatorizado para investigar la eficacia, seguridad y tolerabilidad de ZK 230211 (100 mg frente a 25 mg) como tratamiento endocrino de segunda línea en mujeres posmenopáusicas con cánc... 2011-03-21 due-trials
Completed, but no date 2005-005989-37 CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis bad-data
Reported results 2006-000394-30 Multicenter study to investigate the bleeding profile and the insertion easiness in women inserted with a second consecutive MIRENA for contraception or menorrhagia 2012-10-18 due-trials
Reported results 2006-004824-35 A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum 2007-05-23 due-trials
Reported results 2006-005270-47 Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do... 2008-06-17 due-trials
Reported results 2006-006199-39 A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17β-estradiol [E2] / 0.25 mg drospire... 2009-08-17 due-trials
Trial is outside EEC, and reported results 2014-004917-10 A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Multicenter Clinical Trial To Evaluate Efficacy And Safety Of Mometasone Furoate Nasal Spray In Children With Adenoid Hypertrophy. SNORE ... bad-data
Trial is outside EEC, and reported results 2014-004921-41 Multicenter, double-blind, randomized, placebo-controlled study of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis bad-data
Trial is outside EEC, and reported results 2014-004922-16 A study of long-term (12-24 weeks) administration of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis (Protocol No. P06333) bad-data
Trial is outside EEC, and reported results 2014-004923-40 Double blind, placebo controlled trial, evaluating the role of Nasonex® in the management of nasal obstruction secondary to adenoids hypertrophy in children. bad-data
Trial is outside EEC, and reported results 2014-004926-17 OPEN LABEL, 12-WEEK CLINICAL TRIAL TO ASSESS EFFICACY, SAFETY, TREATMENT ADHERENCE AND QUALITY OF LIFE IMPACT ON MOMETASONE FUROATE DRY POWDER 400 MCG ONCE DAILY IN PERSISTENT MILD-MODERATE ASTHMATIC ... bad-data

Related organisations

Over time organisations can merge, or split.

We think Schering AG is now effectively part of Bayer.